Click on a filter below to refine your search. Remove a filter to broaden your search.
Baricitinib plus remdesivir was linked to a reduced risk of death and progression to invasive mechanical ventilation.
A reduced risk was seen for venous thromboembolism, arterial thrombosis/thromboembolism and heart failure.
In New England and the Pacific, prevalence tended to be lower, whereas higher prevalence was seen in the South, Midwest and West.
Vaccine effectiveness was 49% at 60 to 119 days after vaccination among tests exhibiting spike gene target failure.
No reason other than mild symptoms was given for almost half of patients at high risk for progression who were not offered treatment.